NeoGenomics, Inc.: NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation

FT. MYERS, FL / ACCESSWIRE / May 28, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced availability of the QIAGEN therascreen PI...